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Abstract
Background
Pulmonary nodule guidelines do not indicate how to individualize follow-up according to
comorbidity or life expectancy.
Objectives
To characterize comorbidity and life expectancy in older veterans with incidental, symptom-
detected, or screen-detected nodules in 2008–09 compared to 2013–14. To determine the
impact of these patient factors on four-year nodule follow-up among the 2008–09 subgroup.
Design
Retrospective cohort study.
Setting
Urban Veterans Affairs Medical Center.
Participants
243 veterans age65 with newly diagnosed pulmonary nodules in 2008–09 (followed for
four years through 2012 or 2013) and 446 older veterans diagnosed in 2013–14.
Measurements
The primary outcome was receipt of any follow-up nodule imaging and/or biopsy within four
years after nodule diagnosis. Primary predictor variables included age, Charlson-Deyo
Comorbidity Index (CCI), and life expectancy. Favorable life expectancy was defined as age
65–74 with CCI 0 while limited life expectancy was defined as age85 with CCI1 or age
65 with CCI4. Interaction by nodule size was also examined.
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Results
From 2008–09 to 2013–14, the number of older veterans diagnosed with new pulmonary
nodules almost doubled, including among those with severe comorbidity and limited life
expectancy. Overall among the 2008–09 subgroup, receipt of nodule follow-up decreased
with increasing comorbidity (CCI4 versus 0: adjusted RR 0.61, 95% CI 0.39–0.95) with a
trend towards decreased follow-up among those with limited life expectancy (adjusted RR
0.69, 95% CI 0.48–1.01). However, we detected an interaction effect with nodule size such
that comorbidity and life expectancy were associated with decreased follow-up only among
those with nodules6 mm.
Conclusions
We found some individualization of pulmonary nodule follow-up according to comorbidity
and life expectancy in older veterans with smaller nodules only. As increased imaging
detects nodules in sicker patients, guidelines need to be more explicit about how to best
incorporate comorbidity and life expectancy to maximize benefits and minimize harms for
patients with nodules of all sizes.
Introduction
Over 1.5 million Americans are diagnosed with incidental pulmonary nodules annually
[1]. With implementation of lung cancer screening and new indications for CT imaging,
even more patients will be diagnosed with nodules, especially older adults. For example,
the US Preventive Services Task Force (USPSTF) lung cancer screening recommendation
[2] focuses on high-risk adults age 55 to 80 years. Neither the Fleischner Society guidelines
[3, 4] for incidental nodules nor the Lung Computed Tomography (CT) Screening Report-
ing and Data System (Lung-RADS) [5] guideline for screen-detected nodules provide
detailed information on how to incorporate age, comorbidity, or life expectancy to individ-
ualize nodule follow-up. As increasing numbers of older patients and their providers face
these clinical challenges, it is important to characterize comorbidity and life expectancy in
older adults with pulmonary nodules and how these patient factors impact nodule follow-
up.
Prior studies on the impact of age and comorbidity on pulmonary nodule follow-up have
been limited. A retrospective study of veterans with incidental or symptomatic nodules in
2003–06 found that older age was associated with less intensive follow-up than recommended
by guidelines [6]. However, chronic obstructive pulmonary disease (COPD) was the only
comorbidity examined. Another retrospective study of incidental pulmonary nodules diag-
nosed in 2007 found that follow-up nodule imaging did not differ by age [7]. However, this
study did not examine any comorbidities. No studies have examined the impact of multiple
comorbidities or life expectancy on nodule follow-up.
We performed a retrospective cohort study to a) characterize age, comorbidity, and life
expectancy among veterans age65 with newly diagnosed incidental, symptom-detected, or
screen-detected pulmonary nodules in 2008–09 compared to 2013–14 and b) determine the
impact of age, comorbidity, and life expectancy on four-year follow-up among the 2008–09
subgroup.
Pulmonary nodules in older veterans
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Methods
Data sources and patients
We identified veterans age65 years with newly diagnosed pulmonary nodules (solitary or
multiple) on CT chest scan at the San Francisco Veterans Affairs Medical Center (SFVAMC)
in 2008–09 and 2013–14. The years 2008–09 were selected to represent patterns of pulmonary
nodule diagnosis and evaluation prior to the 2013 USPSTF lung cancer screening recommen-
dation [2]. The years 2013–14 were selected to represent patterns of pulmonary nodule diag-
nosis after the screening recommendation changed. At the SFVAMC, patients with high-risk
nodules are referred to chest clinic while those with low-risk nodules are managed by primary
care with assistance from a nurse practitioner-led nodule tracking program.
We queried radiology CT chest reports with search terms “nodul” and/or “mass” and man-
ually reviewed to confirm the presence of a new pulmonary nodule. Exclusion criteria included
patients with a history of invasive cancer, pulmonary nodules previously identified on CT
imaging, nodules of other organs (e.g. thyroid), and nodules with benign patterns of calcifica-
tion (e.g., granulomas). Demographics and vital status were obtained from the VA National
Patient Care Database.
Our initial search identified 2,058 patients with CT chest reports that met the search terms.
After manual review, 1,369 patients were excluded, resulting in a final cohort of 689 patients:
243 patients in 2008–09 and 446 patients in 2013–14 (Fig 1).
The University of California, San Francisco Institutional Review Board and the SFVAMC
Research and Development Committee approved this study and provided a waiver of consent
because obtaining informed consent from patients was not practical given the large number of
Fig 1. Exclusions used to define the final cohort of older veterans with a newly diagnosed pulmonary nodule at the SFVAMC in 2008–09 and 2013–14.
https://doi.org/10.1371/journal.pone.0200496.g001
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required records for this minimal risk study. Identifiable data was abstracted from the medical
record and deidentified prior to analysis.
Data collection and measurement
Baseline characteristics. Age at the index CT scan was categorized as 65–74, 75–84, or
85 years. Comorbidity was assessed using the Charlson-Deyo Comorbidity Index (CCI) [8],
a summary measure of 19 chronic diseases weighted according to their association with mor-
tality [9]. Malignancy and metastatic disease did not contribute to the CCI in this study
because patients with a history of invasive cancer were excluded. The CCI was calculated based
on inpatient and outpatient VA claims during the 12 months prior to the index CT scan.
Patients were categorized as having no comorbidity (CCI 0), average (CCI 1–3), or severe
comorbidity (CCI4).
Patients were categorized as having limited life expectancy (estimated <5 years) if age was
85 with CCI1 or if age was65 with CCI4. Patients were categorized as having favor-
able life expectancy (estimated >10 years) if age was 65–74 with CCI 0. The remaining patients
were categorized as having intermediate life expectancy. These categories have been used in
previous studies to examine how extremes of health status influence cancer screening.[10–12]
Smoking history at the index CT scan (never, former, current smoker) was abstracted from
medical record notes.
Baseline pulmonary nodule characteristics were abstracted from the index radiology report
and medical record. Patients were categorized as having an incidental nodule if the index CT
scan was performed for a reason unrelated to pulmonary nodules (e.g., pulmonary embolism,
aortic aneurysm evaluation), a symptom-detected nodule if the index scan was performed for
symptoms potentially attributable to pulmonary nodules or suspected malignancy (e.g., cough,
weight loss), or a screen-detected nodule if they underwent imaging for lung cancer screening
or VA-related health screening (e.g., Agent Orange exposure). Nodule quality was categorized
as solid, ground glass, or mixed. Nodule size for the largest dominant nodule was abstracted
from the radiology report and categorized as4 mm,>4–6 mm, >6–8 mm, and>8 mm
according to Fleischner guideline size categories [3]. The presence of spiculation, dominant
nodule in the upper lobe, multiple nodules, chest lymphadenopathy, and suspected infection
was also determined.
Outcome variables. For the subgroup of patients with newly diagnosed pulmonary nod-
ules in 2008–09, we linked VA and Medicare claims to capture nodule follow-up. Patients
were followed for four years, or until the first diagnosis of invasive cancer or death.
We identified follow-up nodule imaging (CT chest and/or PET scans) and biopsy (transcu-
taneous, transbronchial, or surgical) using CPT and ICD-9 procedure codes. Medical records
were reviewed to confirm that imaging and biopsies were follow-up of the index pulmonary
nodule(s). Biopsy complications were also abstracted. Because some patients proceeded
directly from index CT scan to biopsy without additional surveillance imaging, we examined
receipt of any follow-up nodule imaging and/or biopsy as a composite primary outcome. Pul-
monary nodule diagnostic outcomes were categorized as lung cancer, other type of cancer, or
no cancer diagnosis.
Statistical analysis
To evaluate differences across diagnosis year groups (2008–09 versus 2013–14), patient and
nodule characteristics were compared using chi-square or Fisher’s exact tests.
For the patients with newly diagnosed pulmonary nodules in 2008–09, we performed uni-
variable and multivariable Poisson regression models with robust error variances [13] to
Pulmonary nodules in older veterans
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determine associations of patient and baseline nodule characteristics with receipt of nodule
follow-up. The multivariable model adjusted for all patient and nodule characteristics except
life expectancy since it is a composite predictor created from age and comorbidity. The multi-
variable model for life expectancy adjusted for all patient and nodule characteristics except age
and comorbidity. For ordinal predictor variables, linear trend tests were also performed. In
addition, we checked for an interaction effect between comorbidity/life expectancy and nodule
size.
The threshold of P<0.05 was used to determine statistical significance for all two-sided
comparisons. Analyses were conducted with SAS v9.2 (SAS Institute, Cary, NC).
Results
Patient and nodule characteristics
Our cohort included a total of 689 veterans age65 with a newly diagnosed pulmonary nodule
(243 veterans in 2008–09, 446 veterans in 2013–14). Median age was 73 (IQR 68–81) in 2008–
09 and 70 (IQR 66–76) in 2013–14. In 2008–09, 129 patients (53.1%) had a CCI of 0 and 22
(9.0%) had a CCI4. In 2013–14, 197 patients (44.2%) had a CCI of 0 and 44 (9.9%) had a
CCI4 (P = 0.08) (Table 1). The most common comorbidities were COPD, diabetes, and
congestive heart failure. In 2008–09, 75 (30.9%) of patients had a favorable life expectancy
while 33 (13.6%) had a limited life expectancy. In 2013–14, 142 patients (31.8%) had a favor-
able life expectancy while 67 (15.0%) had a limited life expectancy (P = 0.80). The majority of
patients were former smokers (65.4% in 2008–09, 58.2% in 2013–14).
Symptoms were the most common reason for nodule detection (56.0%) in 2008–09 and
incidental findings (49.6%) were most common in 2013–14 (P<0.001). In 2008–09, incidental
nodules were most commonly detected on CT chest scans to evaluate vasculature (14.8%, e.g.,
pulmonary embolism, aortic dissection) and perioperatively (13.2%). In 2013–14, incidental
nodules were also identified on CT chest scans for new indications including transcatheter
aortic valve replacement (TAVR) planning (5.4%) and other cardiac evaluation (5.4%).
Screen-detected nodules increased from 1.2% in 2008–09 to 15.3% in 2013–14, primarily with
the implementation of lung cancer screening. Of note, among patients with screen-detected
nodules, only 2 patients (3%) in 2013–14 met criteria for limited life expectancy. From 2008–
09 to 2013–14, pulmonary nodules were smaller in size with 67.5% of patients with nodules
6 mm in 2008–09 and 72.7% in 2013–14 (P = 0.03). Additionally, patients in 2013–14 were
more likely to have multiple nodules (68.8%) compared to patients in 2008–09 (56.4%;
P = 0.001).
Nodule follow-up
In the subgroup of 243 patients with newly diagnosed nodules in 2008–09, 134 patients
(55.1%) underwent a total of 297 CT chest and 31 PET scans during four-year follow-up (Fig
2). A total of 51 patients (21.0%) underwent a nodule-related biopsy during four-year follow-
up, the majority of which were transcutaneous. Median time from index CT scan to first fol-
low-up nodule imaging or biopsy was 11.5 months (IQR 3.0 months to not reached). The
biopsy complication rate was 13.7%: 3 pneumothoraces requiring chest tube, 2 bleeds, 1 aspira-
tion, and 1 post-procedure seizure. Ultimately, 42 patients overall were diagnosed with lung
cancer (12.5% of patients with incidental nodules, 21.3% of patients symptom-detected nod-
ules) and 19 were diagnosed with other types of cancer (6.7% of incidental nodules, 8.1% of
symptom-detected nodules), leaving 182 patients (74.9%) without cancer. The most common
cause of death was non-cancer related (23.0%), while 13.2% died of lung cancer and 4.9% died
of other cancers.
Pulmonary nodules in older veterans
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Table 1. Patient and baseline pulmonary nodule characteristics in veterans age65 with newly diagnosed pulmonary nodule(s) by diagnosis year group (N = 689).
2008–09 2013–14 b
(n = 243) (n = 446)
Characteristica No. (%) No. (%) P
Age at pulmonary nodule diagnosis, year 0.001
65–74 132 (54.3) 306 (68.6)
75–84 82 (33.7) 106 (23.8)
85 29 (11.9) 34 (7.6)
Charlson Comorbidity Index 0.08
0 129 (53.1) 197 (44.2)
1–3 92 (37.9) 205 (46.0)
4 22 (9.0) 44 (9.9)
Selected Charlson comorbidities
COPD 53 (21.8) 124 (27.8) 0.09
Diabetes (with/without complications) 40 (16.4) 85 (19.1) 0.40
Congestive heart failure 32 (13.2) 53 (11.9) 0.62
Moderate or severe renal disease 28 (11.5) 49 (11.0) 0.83
Cerebrovascular disease 21 (8.6) 30 (6.7) 0.36
Peripheral vascular disease 18 (7.4) 48 (10.8) 0.15
Myocardial infarct 14 (5.8) 21 (4.7) 0.55
Mild liver disease 4 (1.7) 7 (1.6) 1.00c
Ulcer disease 2 (0.8) 10 (2.2) 0.23c
Moderate or severe liver disease 2 (0.8) 2 (0.5) 0.62c
Connective tissue disease 1 (0.4) 6 (1.4) 0.43c
Dementia 1 (0.4) 5 (1.1) 0.67c
Hemiplegia 1 (0.4) 0 (0) 0.35c
AIDS 0 (0) 5 (1.1) 0.17c
Life expectancy 0.80
Favorable 75 (30.9) 142 (31.8)
Intermediate 135 (55.5) 237 (53.1)
Limited 33 (13.6) 67 (15.0)
Male gender 237 (97.5) 432 (96.9) 0.62
Race 0.01
White 183 (76.9) 364 (84.9)
Black 27 (11.3) 40 (9.3)
Other 28 (11.8) 25 5.8)
Married 98 (41.0) 171 (39.1) 0.63
Lived in ZCTA in which25% of adults had a college education 169 (72.5) 281 (64.8) 0.04
Median annual income of ZCTA 0.19
Lowest tertile 68 (29.2) 155 (35.7)
Middle tertile 80 (34.3) 144 (33.2)
Highest tertile 85 (36.5) 135 (31.1)
Smoking history 0.17
Never smoker 41 (16.9) 88 (19.8)
Former smoker 159 (65.4) 259 (58.2)
Current smoker 43 (17.7) 98 (22.0)
(Continued)
Pulmonary nodules in older veterans
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In unadjusted analyses (Table 2), there was no association between age and the receipt of
follow-up nodule imaging and/or biopsy. Nodule follow-up was less likely with increasing
comorbidity (CCI 1–3: RR 0.79, 95% CI 0.63–0.98; CCI4: RR 0.59, 95% CI 0.35–0.99; test
for linear trend P = 0.05). Patients with limited life expectancy were also less likely to undergo
nodule follow-up compared to those with favorable life expectancy (RR 0.64, 95% CI 0.43–
0.96). In addition, nodule follow-up was more likely for former (RR 1.74, 95% CI 1.14–2.64)
and current smokers (RR 2.03, 95% CI 1.31–3.16) compared to never smokers (test for linear
trend P = 0.002) as well as for patients with high-risk nodule characteristics (i.e., larger size
and spiculation). In contrast, nodule follow-up was less likely for patients with multiple nod-
ules and suspected infection. There were no differences in nodule follow-up according to
other demographic variables.
Table 1. (Continued)
2008–09 2013–14 b
(n = 243) (n = 446)
Characteristica No. (%) No. (%) P
Reason for nodule detection <0.001
Incidental 104 (42.8) 221 (49.6)
Vascular evaluationd 36 (14.8) 59 (13.2)
Perioperative 32 (13.2) 39 (8.7)
Abdominal CT 13 (5.3) 48 (10.8)
Cardiac evaluatione 3 (1.2) 24 (5.4)
TAVR 0 (0) 24 (5.4)
Other 20 (8.2) 27 (6.1)
Symptom-detected 136 (56.0) 157 (35.2)
Screen-detected 3 (1.2) 68 (15.3)
Lung cancer screening 2 (0.1) 42 (9.4)
VA-related screening 1 (0.04) 26 (5.8)
Nodule quality 0.09
Solid 207 (85.2) 388 (87.0)
Ground glass 16 (6.6) 14 (3.1)
Mixed 20 (8.2) 44 (9.9)
Maximum nodule size 0.03
4 mm 110 (45.3) 229 (51.4)
4–6 mm 54 (22.2) 95 (21.3)
>6–8 mm 16 (6.6) 45 (10.1)
>8 mm 63 (25.9) 77 (17.3)
Spiculated dominant nodule 18 (7.4) 28 (6.3) 0.57
Upper lobe location 101 (41.6) 190 (42.6) 0.79
Multiple nodules 137 (56.4) 307 (68.8) 0.001
Suspicious chest lymphadenopathy 39 (16.1) 51 (11.4) 0.09
Infection suspected 26 (10.7) 59 (13.2) 0.34
Abbreviations: COPD, chronic obstructive pulmonary disorder; TAVR, transcatheter aortic valve replacement; ZCTA, zip code tabulation area.
aThe following variables had missing data: race (3.2%), marital status (1.9%), ZCTA college education (3.2%), median annual income (3.2%), and smoking history
(0.2%).
bDifferences between 2008–09 and 2013–14 diagnosis year groups were tested using chi-square test, unless otherwise indicated.
cDifferences between 2008–09 and 2013–14 diagnosis year groups tested using Fisher’s exact test.
dVascular evaluation such as imaging for pulmonary embolism or aortic dissection.
eCardiac evaluation such as imaging for coronary calcium.
https://doi.org/10.1371/journal.pone.0200496.t001
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In adjusted analyses (Table 2), the association between comorbidity and receipt of nodule
follow-up remained statistically significant only for CCI4 compared to CCI 0 (adjusted RR
0.61, 95% CI 0.39–0.95). The association with CCI 1–3 no longer reached statistical signifi-
cance (adjusted RR 0.85, 95% CI 0.68–1.08). Similarly, the association with limited life expec-
tancy no longer reached statistical significance (adjusted RR 0.69, 95% CI 0.48–1.01) after
adjustment. Smoking history, nodule size >8 mm, and spiculation remained strong predictors
of nodule follow-up in the adjusted analyses. In the adjusted analysis, patients with mixed nod-
ules were more likely to receive nodule follow-up than patients with solid nodules (adjusted
RR 1.43, 95% CI 1.00–2.05, P = 0.05).
In addition, an interaction effect of life expectancy and nodule size on nodule follow-up
was detected (P = 0.05) such that patients with limited life expectancy were less likely to receive
follow-up only if they had smaller nodules6 mm (Fig 3). In contrast, for patients with nod-
ules>6 mm, there was no difference in nodule follow-up by life expectancy.
Discussion
We found that the number of older veterans diagnosed with new pulmonary nodules almost
doubled from 2008–09 to 2013–14, which reflects both the implementation of lung cancer
screening [2] and increased imaging use for new indications such as TAVR planning [14] and
cardiac evaluation [15]. Nodules diagnosed in 2013–14 were smaller as well. This increase in
patients with nodules was true even among those with severe comorbidity and limited life
expectancy. Overall, patients with severe comorbidity and limited life expectancy were less
likely to receive nodule follow-up. However, there was an interaction effect of nodule size with
comorbidity and life expectancy; severe comorbidity and limited life expectancy decreased fol-
low-up in patients with smaller nodules (6 mm) but not in those with larger nodules (>6
mm).
To our knowledge, this is the first study to examine the impact of comorbidity and life
expectancy on pulmonary nodule follow-up in an older population. Given the immediate and
potentially substantial harms of intensive pulmonary nodule surveillance and invasive
Fig 2. Four-year follow-up after pulmonary nodule diagnosis in veterans age65 with newly diagnosed pulmonary nodules at the SFVAMC in 2008–09.
https://doi.org/10.1371/journal.pone.0200496.g002
Pulmonary nodules in older veterans
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Table 2. Patient and baseline nodule characteristics associated with receipt of any nodule imaging and/or biopsy during four-year follow-up in veterans age65
with newly diagnosed pulmonary nodule(s) in 2008–09 (n = 243).
Receipt of any follow-up nodule imaging and/or biopsya
No. (%) Unadjusted RR (95% CI) Adjusted RRb
(95% CI)
Age
65–74 83 (62.9) 1.00 1.00
75–84 48 (58.5) 0.93 (0.74–1.17) 0.96 (0.75–1.22)
85 17 (58.6) 0.93 (0.67–1.30) 1.01 (0.68–1.49)
CCI
0 89 (69.0) 1.00d 1.00
1–3 50 (54.4) 0.79 (0.63–0.98) 0.85 (0.68–1.08)
4 9 (40.9) 0.59 (0.35–0.99) 0.61 (0.39–0.95)
Life expectancyc
Favorable 53 (70.7) 1.00d 1.00
Intermediate 80 (59.3) 0.84 (0.68–1.03) 0.85 (0.69–1.04)
Limited 15 (45.5) 0.64 (0.43–0.96) 0.69 (0.48–1.01)
Male gender 144 (60.8) 0.91 (0.51–1.62) 1.02 (0.50–2.10)
Race
White 111 (60.7) 1.00 1.00
Black 19 (70.4) 1.16 (0.88–1.52) 1.16 (0.87–1.54)
Other 16 (57.1) 0.94 (0.67–1.33) 1.06 (0.79–1.43)
Married 56 (57.1) 0.92 (0.74–1.13) 0.96 (0.77–1.19)
Lived in ZCTA in which25% of adults had a college education 103 (61.0) 1.05 (0.83–1.34) 1.12 (0.84–1.51)
Median annual income of ZCTA
Lowest tertile 41 (60.3) 1.00 1.00
Middle tertile 47 (58.8) 0.97 (0.75–1.27) 0.84 (0.61–1.14)
Highest tertile 52 (61.2) 1.01 (0.78–1.31) 0.92 (0.66–1.28)
Smoking history
Never smoker 15 (36.6) 1.00d 1.00d
Former smoker 101 (63.5) 1.74 (1.14–2.64) 1.60 (1.05–2.42)
Current smoker 32 (74.4) 2.03 (1.31–3.16) 1.67 (1.08–2.60)
Symptom-detected nodule 84 (61.8) 1.03 (0.84–1.27) 0.92 (0.73–1.15)
Nodule quality
Solid 127 (61.4) 1.00 1.00
Ground glass 9 (56.3) 0.92 (0.59–1.43) 1.16 (0.75–1.78)
Mixed 12 (60.0) 0.98 (0.67–1.42) 1.43 (1.00–2.05)
Maximum nodule size
4 mm 52 (47.3) 1.00d 1.00d
>4–6 mm 31 (57.4) 1.21 (0.90–1.64) 1.21 (0.89–1.63)
>6–8 mm 12 (75.0) 1.59 (1.12–2.24) 1.47 (0.98–2.19)
>8 mm 53 (84.1) 1.78 (1.42–2.23) 1.54 (1.16–2.05)
Spiculation 17 (94.4) 1.62 (1.39–1.90) 1.29 (1.01–1.63)
Upper lobe location 67 (66.3) 1.16 (0.95–1.42) 1.13 (0.91–1.39)
Multiple nodules 74 (54.0) 0.77 (0.63–0.94) 0.93 (0.75–1.14)
Chest lymphadenopathy 28 (71.8) 1.22 (0.97–1.53) 1.17 (0.89–1.54)
(Continued)
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procedures, decreased nodule follow-up among patients with severe comorbidity and limited
life expectancy may represent appropriate individualization of nodule evaluation where the
risks of nodule follow-up outweigh the chance of benefit. Of note, the majority of patients with
screen-detected nodules had favorable or intermediate life expectancy with only 3% having
limited life expectancy. This is consistent with the USPSTF recommendation to discontinue
lung cancer screening among patients with health problems that substantially limit their life
expectancy [2].
While it is not known how life expectancy impacts the likelihood of harms from pulmonary
nodule follow-up, the potential harms of nodule follow-up in the general population are well
documented and a few studies have described harms according to age and comorbidity. In a
study of transcutaneous biopsy, the risk of pneumothorax requiring chest tube was estimated
at 6.6% with an overall 15% risk of any pneumothorax [16]. In studies of transbronchial
Table 2. (Continued)
Receipt of any follow-up nodule imaging and/or biopsya
No. (%) Unadjusted RR (95% CI) Adjusted RRb
(95% CI)
Suspected infection 7 (26.9) 0.41 (0.22–0.79) 0.55 (0.29–1.07)
Abbreviations: CCI, Charlson Comorbidity Index; RR, relative risk; ZCTA, zip code tabulation area.
aUsing Poisson regression with robust error variances.
bAdjusted models included all patient and nodule characteristics except life expectancy.
cAdjusted model for life expectancy included all patient and nodule characteristics except age and CCI.
dTest for linear trend P< 0.05.
https://doi.org/10.1371/journal.pone.0200496.t002
Fig 3. Receipt of any follow-up nodule imaging and/or biopsy during four-year follow-up in older veterans with newly
diagnosed pulmonary nodules by life expectancy and nodule size. Patients were categorized as having limited life expectancy
if age was85 with CCI1 or if age was65 with CCI4. Patients were categorized as having favorable life expectancy if age
was 65–74 with CCI 0. The remaining patients were categorized as having intermediate life expectancy.
https://doi.org/10.1371/journal.pone.0200496.g003
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biopsy, the overall complication rate ranged from 1.4–7.1% [17, 18]. Studies on the association
between older age and transbronchial biopsy complications have been mixed. While older age
was not associated with increased risk of transbronchial biopsy complications in a UK study
[18], older age was associated with escalation of level of care after the procedure (i.e., hospital
admission, ICU transfer) in a national US study [17] and with biopsy-related hemorrhage in a
study of community hospitals in Florida [19]. Additionally, patients with renal failure and cir-
rhosis were at increased risk of hemorrhage while those with COPD were at increased risk of
pneumothorax from transbronchial biopsy [19].
Potential harms of nodule follow-up are not limited to procedural complications. In a mul-
ticenter study of patients with incidental nodules, 26% of patients reported clinically signifi-
cant nodule-related distress [20], which highlights the important psychosocial impact of
nodule follow-up [21]. Misperceptions about nodules, the natural history, and likelihood of
cancer were also common [20]. For example, only 25% of patients accurately estimated their
risk of lung cancer and 71% were unaware of the possibility of indolent tumors. In that study,
older patients were not more likely to report nodule-related distress [20], but the impact of
comorbidity and life expectancy on nodule-related distress remains unknown. Overdiagnosis
of indolent tumors [22], which may otherwise not cause clinical symptoms, is an additional
potential harm of nodule follow-up. The potential harm of overdiagnosis is particularly impor-
tant to consider for patients with limited life expectancy, where competing causes of death
from other comorbidities may limit the potential benefits of nodule evaluation and possible
subsequent cancer treatment [23, 24].
The potential harms of nodule follow-up are especially salient when the nodules detected
are smaller with a lower risk of lung cancer [3, 4, 6], which may tip the balance from benefits
towards possible harm. Indeed, we found that the impact of comorbidity and life expectancy
on nodule follow-up differed by nodule size such that comorbidity and limited life expectancy
were associated with decreased nodule follow-up only for patients with smaller nodules. We
hypothesize that providers in our study were more comfortable deferring nodule follow-up for
these smaller nodules given their lower risk of lung cancer [3, 4, 6]. However, for larger nod-
ules, patients received nodule follow-up regardless of life expectancy. While this may be appro-
priate given the increased risk of lung cancer with increasing nodule size [3, 4], further
research is needed to determine how incorporating comorbidity and life expectancy into deci-
sion-making for nodules of all sizes may impact patient outcomes.
Older age alone was not associated with decreased nodule follow-up in our study of veter-
ans age65. This finding differs from a retrospective study of veterans of all ages (mean age
66, SD 11 years) diagnosed with pulmonary nodules in 2003–06 [6]. In that study, older age
was associated with less intensive nodule follow-up than recommended by guidelines [3].
However, without comprehensively adjusting for comorbidities, which are more common
with older age, their result is difficult to interpret since residual confounding may be present.
Since the risk of lung cancer increases with age [25], our study’s lack of a potential age bias in
nodule follow-up in both the unadjusted and adjusted analyses is reassuring.
In contrast to age, smoking history and nodule characteristics (e.g., size, spiculation) were
strong predictors of nodule follow-up. These findings are consistent with the 2005 Fleischner
Society guidelines [3] for management of incidental pulmonary nodules where recommenda-
tions are primarily based on nodule size and smoking history. While the 2005 Fleischner
guidelines state that the “patient’s age and the presence of comorbid conditions should influ-
ence management recommendations,” [3] no specific guidance on how to do so is provided.
Fortunately, the 2017 revision of the Fleischner guidelines [4] allows for more patient and pro-
vider discretion in nodule management by providing a range of follow-up intervals rather than
precise times. In addition, routine follow-up for nodules <6 mm, which may represent
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overdiagnosis, is no longer recommended unless high risk features are present. Together, these
improvements to the guidelines may help decrease the potential harms of nodule follow-up
among patients with severe comorbidity and limited life expectancy while preserving the
potential clinical benefit for older adults in good health with favorable life expectancy who
may benefit most. We found that patients with mixed nodules were more likely to receive nod-
ule follow-up than patients with solid nodules. This is surprising since the risk of invasive lung
cancer is generally lower with mixed nodules depending on the size of the solid component
compared to solid nodules [26]. The association between mixed nodules and increased nodule
follow-up only emerged after adjustment for patient and nodule characteristics, suggesting the
presence of negative confounding that attenuated the true association.
Our study has a number of strengths, including a comparison of patient and nodule charac-
teristics over time and a comprehensive examination of the impact of age, comorbidity, and
life expectancy on pulmonary nodule evaluation.
However, it also has several limitations. First, as a single center study of pulmonary nodule
evaluation at an urban VA medical center, practice patterns may differ from other VA and
non-VA medical centers. However, the high rates of older adults, current or former smokers,
and severe comorbidity among veterans make them an ideal population for our research ques-
tions. Second, due to the small number of biopsy complications, we did not have sufficient
power to examine predictors of biopsy complications in this study. Lastly, we examined four-
year follow-up only for the subgroup of patients with newly diagnosed pulmonary nodules in
2008–09 with outcomes through 2013. Data are not yet available to examine four-year follow-
up for the subgroup with newly diagnosed pulmonary nodules in 2013–14 after implementa-
tion of lung cancer screening and the Lung-RADS guideline. However, since over 90% of the
new pulmonary nodules identified in our 2013–14 subgroup were unrelated to lung cancer
screening, future studies of nodule management in routine clinical care should examine inci-
dental and symptom-detected nodules in addition to screen-detected nodules.
Conclusions
As the number of older patients diagnosed with pulmonary nodules increases over time, nod-
ule follow-up can be individualized by considering comorbidity and life expectancy for all
patients, not just those with smaller nodules. Pulmonary nodule guidelines, for both incidental
nodules and screen-detected nodules, need to be more explicit about how to best incorporate
comorbidity and life expectancy information together with smoking history and nodule char-
acteristics to determine when and how to follow-up a pulmonary nodule. Better individualized
care for older adults with pulmonary nodules will maximize benefits and reduce harms of this
increasingly common clinical management challenge.
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